Trials / Completed
CompletedNCT01141179
The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The study will investigate the impact of reduced renal function on the pharmacokinetic and pharmacodynamic profile of LEO 27847. Volunteers with different degrees of renal impairment will be administered one dose of the investigational drug and then followed until investigational drug is eliminated from the body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEO 27847 | 2 mL (0.1 mg) dose of oral solution |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2011-02-01
- Completion
- 2011-02-01
- First posted
- 2010-06-10
- Last updated
- 2025-02-24
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01141179. Inclusion in this directory is not an endorsement.